Last reviewed · How we verify
tolododekin alfa — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
tolododekin alfa (tolododekin alfa) — Ankyra Therapeutics, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| tolododekin alfa TARGET | tolododekin alfa | Ankyra Therapeutics, Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- tolododekin alfa CI watch — RSS
- tolododekin alfa CI watch — Atom
- tolododekin alfa CI watch — JSON
- tolododekin alfa alone — RSS
Cite this brief
Drug Landscape (2026). tolododekin alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/tolododekin-alfa. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab